orforglipron vs oral semaglutide A clinical trial for diabetes that pit orforglipron, a diabetes and weight-loss pill developed by Eli Lilly, against semaglutide, made by Novo Nordisk, suggests the former pill may have the edge Why Novo Nordisk and Eli

Diabetes: An Old Disease A New Insight 111 Keating GM (2010) Vildagliptin: a review of its use in type 2 diabetes mellitus

However, market and insurance plays a large role in determining the cost per patient

Wondering how to vet peptide suppliers in general

Decisions at this level carry real consequences for millions of lives, and they demand not only leadership, but a profound respect for evidence, expertise, and the complexity of medicine

Drugs compounded in outsourcing facilities are subject to current good manufacturing practice (CGMP) requirements. According to safety guidelines on Hims & Hers Healths website, their compounded drugs are produced exclusively in FDA-regulated 503B facilities. I knew exactly what the supply chain looked like